Bereich
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study.
Goetz M, Cicin I, Testa L, Tolaney S, Huober J, Guarneri V, Johnston S, Martín M, Rastogi P, Harbeck N, Shahir A, Wei R, Andre V, Rugo H, O'Shaughnessy J. Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study. NPJ Breast Cancer 2024; 10:34.
26.04.2024Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study.
26.04.2024NPJ Breast Cancer 2024; 10:34
Goetz Matthew P, Cicin Irfan, Testa Laura, Tolaney Sara M, Huober Jens, Guarneri Valentina, Johnston Stephen R D, Martín Miguel, Rastogi Priya, Harbeck Nadia, Shahir Ashwin, Wei Ran, Andre Valerie A M, Rugo Hope S, O'Shaughnessy Joyce
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
Meyer-Wilmes P, Huober J, Untch M, Blohmer J, Janni W, Denkert C, Klare P, Link T, Rhiem K, Bayer C, Reinisch M, Bjelic-Radisic V, Zahm D, Hanusch C, Solbach C, Heinrich G, Hartkopf A, Schneeweiss A, Fasching P, Filmann N, Nekljudova V, Holtschmidt J, Stickeler E, Loibl S. Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). ESMO Open 2024; 9:103009.
24.04.2024Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
24.04.2024ESMO Open 2024; 9:103009
Meyer-Wilmes P, Huober Jens, Untch Michael, Blohmer J-U, Janni Wolfgang, Denkert Carsten, Klare Peter, Link Theresa, Rhiem Kerstin, Bayer C, Reinisch Mattea, Bjelic-Radisic Vesna, Zahm Dirk Michael, Hanusch Claus, Solbach Christine, Heinrich Georg, Hartkopf Andreas D, Schneeweiss Andreas, Fasching Peter Andreas, Filmann N, Nekljudova Valentina, Holtschmidt J, Stickeler Elmar, Loibl Sibylle
Baseline CD4 and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients.
Massa C, Karn T, Weber K, Schneeweiss A, Hanusch C, Blohmer J, Zahm D, Jackisch C, van Mackelenbergh M, Thomalla J, Marme F, Huober J, Müller V, Schem C, Mueller A, Stickeler E, Biehl K, Fasching P, Untch M, Loibl S, Denkert C, Seliger B. Baseline CD4 and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients. Clin Transl Med 2024; 14:e1617.
01.04.2024Baseline CD4 and expansion of γδ T cells correlate with response to durvalumab in triple-negative breast cancer patients.
01.04.2024Clin Transl Med 2024; 14:e1617
Massa Chiara, Karn Thomas, Weber Karsten E, Schneeweiss Andreas, Hanusch Claus, Blohmer Jens-Uwe, Zahm Dirk-Michael, Jackisch Christian, van Mackelenbergh Marion T, Thomalla Jörg, Marme Frederik, Huober Jens, Müller Volkmar, Schem Christian, Mueller Anja, Stickeler Elmar, Biehl Katharina, Fasching Peter Andreas, Untch Michael, Loibl Sibylle, Denkert Carsten, Seliger Barbara
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
Fernandez-Martinez A, Rediti M, Tang G, Pascual T, Hoadley K, Venet D, Rashid N, Spears P, Islam N, El-Abed S, Bliss J, Lambertini M, Di Cosimo S, Huober J, Goerlitz D, Hu R, Lucas P, Swain S, Sotiriou C, Perou C, Carey L. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials. JAMA Oncol 2024
28.03.2024Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
28.03.2024JAMA Oncol 2024
Fernandez-Martinez Aranzazu, Rediti Mattia, Tang Gong, Pascual Tomás, Hoadley Katherine A, Venet David, Rashid Naim U, Spears Patricia A, Islam N, El-Abed Sarra, Bliss Judith, Lambertini Matteo, Di Cosimo Serena, Huober Jens, Goerlitz David, Hu Rong, Lucas Peter C, Swain Sandra M, Sotiriou Christos, Perou Charles M, Carey Lisa A
Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference-a German expert perspective.
Krug D, Banys-Paluchowski M, Brucker S, Denkert C, Ditsch N, Fasching P, Haidinger R, Harbeck N, Heil J, Huober J, Jackisch C, Janni W, Kolberg H, Loibl S, Luftner D, van Mackelenbergh M, Radosa J, Reimer T, Welslau M, Wuerstlein R, Untch M, Budach W. Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference-a German expert perspective. Strahlenther Onkol 2024
23.02.2024Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference-a German expert perspective.
23.02.2024Strahlenther Onkol 2024
Krug David, Banys-Paluchowski Maggie, Brucker Sara Y, Denkert Carsten, Ditsch Nina, Fasching Peter Andreas, Haidinger Renate, Harbeck Nadia, Heil Jörg, Huober Jens, Jackisch Christian, Janni Wolfgang, Kolberg Hans-Christian, Loibl Sibylle, Luftner Diana, van Mackelenbergh Marion T, Radosa Julia C, Reimer Toralf, Welslau Manfred, Wuerstlein Rachel, Untch Michael, Budach Wilfried
Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?-Reply.
Huober J, Thürlimann B, Dietrich D. Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?-Reply. JAMA Oncol 2024
08.02.2024Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?-Reply.
08.02.2024JAMA Oncol 2024
Huober Jens, Thürlimann Beat, Dietrich Daniel
A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.
Mastall M, Roth P, Bink A, Maranta A, Läubli H, Hottinger A, Hundsberger T, Migliorini D, Ochsenbein A, Seystahl K, Imbach L, Hortobágyi T, Held L, Weller M, Wirsching H. A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol. BMC cancer 2024; 24:82.
15.01.2024A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.
15.01.2024BMC cancer 2024; 24:82
Mastall Maximilian, Roth Patrick, Bink Andrea, Maranta Angela Fischer, Läubli Heinz, Hottinger Andreas Felix, Hundsberger Thomas, Migliorini Denis, Ochsenbein Adrian F, Seystahl Katharina, Imbach Lukas L, Hortobágyi Tibor, Held Leonhard, Weller Michael, Wirsching Hans-Georg
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
Rastogi P, O'Shaughnessy J, Martín M, Boyle F, Cortes J, Rugo H, Goetz M, Hamilton E, Huang C, Senkus E, Tryakin A, Cicin I, Testa L, Neven P, Huober J, Shao Z, Wei R, Andre V, Munoz M, San Antonio B, Shahir A, Harbeck N, Johnston S. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. J Clin Oncol 2024:JCO2301994.
09.01.2024Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
09.01.2024J Clin Oncol 2024:JCO2301994
Rastogi Priya, O'Shaughnessy Joyce, Martín Miguel, Boyle Frances, Cortes Javier, Rugo Hope S, Goetz Matthew P, Hamilton Erika, Huang Chiun-Sheng, Senkus Elzbieta, Tryakin Alexey, Cicin Irfan, Testa Laura, Neven Patrick, Huober Jens, Shao Zhimin, Wei Ran, Andre Valerie A M, Munoz Maria, San Antonio Belen, Shahir Ashwin, Harbeck Nadia, Johnston Stephen R D
Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial.
Fehm T, Müller V, Banys-Paluchowski M, Fasching P, Friedl T, Hartkopf A, Huober J, Loehberg C, Rack B, Riethdorf S, Schneeweiss A, Wallwiener D, Meier-Stiegen F, Krawczyk N, Jaeger B, Reinhardt F, Hoffmann O, Müller L, Wimberger P, Ruckhäberle E, Blohmer J, Cieslik J, Franken A, Niederacher D, Neubauer H, Pantel K, Janni W, DETECT study group. Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial. Clin Chem 2024; 70:307-318.
04.01.2024Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial.
04.01.2024Clin Chem 2024; 70:307-318
Fehm Tanja N, Müller Volkmar, Banys-Paluchowski Maggie, Fasching Peter Andreas, Friedl Thomas Wolfram Paul, Hartkopf Andreas D, Huober Jens, Loehberg Christian R, Rack Brigitte, Riethdorf Sabine, Schneeweiss Andreas, Wallwiener Diethelm, Meier-Stiegen Franziska, Krawczyk Natalia, Jaeger Bernadette, Reinhardt Florian, Hoffmann Oliver, Müller Lothar, Wimberger Pauline, Ruckhäberle Eugen, Blohmer Jens-Uwe, Cieslik Jan-Philipp, Franken André, Niederacher Dieter, Neubauer Hans, Pantel Klaus, Janni Wolfgang, DETECT study group
Laser Interstitial Thermal Therapy in a large thalamic glioma with long-term remission: A case report.
Hoyningen A, Koster K, Neidert M, Bozinov O, Lauber A, Kim O, Hundsberger T, Krüger M. Laser Interstitial Thermal Therapy in a large thalamic glioma with long-term remission: A case report. Oncol Res Treat 2023
26.12.2023Laser Interstitial Thermal Therapy in a large thalamic glioma with long-term remission: A case report.
26.12.2023Oncol Res Treat 2023
Hoyningen Alexander, Koster Kira-Lee, Neidert Marian Christoph, Bozinov Oliver, Lauber Arno, Kim Olaf Chan-Hi, Hundsberger Thomas, Krüger Marie Therese
Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer.
Fasching P, Decker T, Hartkopf A, Nusch A, Heinrich B, Kurbacher C, Fuchs R, Tesch H, Krabisch P, Huober J, Kümmel S, Brucker S, Janni W, Schneeweiss A, Schuler M, Fehm T, Luftner D, Quiering C, Voges C, Kreuzeder J, Reinisch M. Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer. Eur J Cancer 2023; 198:113480.
15.12.2023Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer.
15.12.2023Eur J Cancer 2023; 198:113480
Fasching Peter Andreas, Decker Thomas, Hartkopf Andreas D, Nusch Arnd, Heinrich Bernhard J, Kurbacher Christian M, Fuchs Roswitha, Tesch Hans, Krabisch Petra, Huober Jens, Kümmel Sherko, Brucker Sara Y, Janni Wolfgang, Schneeweiss Andreas, Schuler Martin, Fehm Tanja N, Luftner Diana, Quiering Claudia, Voges Claudia, Kreuzeder Julia, Reinisch Mattea
ASO Visual Abstract: Minimally-Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment-A New Concept.
Pfob A, Cai L, Schneeweiss A, Rauch G, Thomas B, Schaefgen B, Kümmel S, Reimer T, Hahn M, Thill M, Blohmer J, Hackmann J, Malter W, Bekes I, Friedrichs K, Wojcinski S, Joos S, Paepke S, Degenhardt T, Rom J, Rody A, van Mackelenbergh M, Banys-Paluchowski M, Große R, Reinisch M, Karsten M, Sidey-Gibbons C, Wallwiener M, Golatta M, Heil J. ASO Visual Abstract: Minimally-Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment-A New Concept. Ann Surg Oncol 2023
13.12.2023ASO Visual Abstract: Minimally-Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment-A New Concept.
13.12.2023Ann Surg Oncol 2023
Pfob André, Cai Lie, Schneeweiss Andreas, Rauch Geraldine, Thomas Bettina, Schaefgen Benedikt, Kümmel Sherko, Reimer Toralf, Hahn Markus, Thill Marc, Blohmer Jens-Uwe, Hackmann John, Malter Wolfram, Bekes Inga, Friedrichs Kay, Wojcinski Sebastian, Joos Sylvie, Paepke Stefan, Degenhardt Tom, Rom Joachim, Rody Achim, van Mackelenbergh Marion T, Banys-Paluchowski Maggie, Große Regina, Reinisch Mattea, Karsten Maria Margarete, Sidey-Gibbons Chris, Wallwiener Markus, Golatta Michael, Heil Jörg
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos M, Boccadoro M, Quach H, Ho P, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof I, van de Donk N, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hájek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen E, Vanquickelberghe V, Sitthi-Amorn A, Van de Velde C, Carson R, Rodriguez-Otero P, Bladé J, Moreau P, PERSEUS Trial Investigators. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med 2023; 390:301-313.
12.12.2023Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
12.12.2023N Engl J Med 2023; 390:301-313
Sonneveld Pieter, Dimopoulos Meletios A, Boccadoro Mario, Quach Hang, Ho P Joy, Beksac Meral, Hulin Cyrille, Antonioli Elisabetta, Leleu Xavier, Mangiacavalli Silvia, Perrot Aurore, Cavo Michele, Belotti Angelo, Broijl Annemiek, Gay Francesca, Mina Roberto, Nijhof Inger, van de Donk Niels W C J, Katodritou Eirini, Schjesvold Fredrik, Sureda Balari Anna, Rosiñol Laura, Delforge Michel, Roeloffzen Wilfried, Silzle Tobias, Vangsted Annette Juul, Einsele Hermann, Spencer Andrew, Hájek Roman, Jurczyszyn Artur, Lonergan Sarah, Ahmadi Tahamtan, Liu Yanfang, Wang Jianping, Vieyra Diego, van Brummelen Emilie M J, Vanquickelberghe Veronique, Sitthi-Amorn Anna, Van de Velde Cornelis J H, Carson Robin, Rodriguez-Otero Paula, Bladé Joan, Moreau Philippe, PERSEUS Trial Investigators
SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial.
Digklia A, Kollár A, Felber Dietrich D, Kronig M, Britschgi C, Rordorf T, Jörger M, Krasniqi F, Metaxas Y, Colombo I, Ribi K, Rothermundt C. SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial. Eur J Cancer 2023; 197:113470.
09.12.2023SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial.
09.12.2023Eur J Cancer 2023; 197:113470
Digklia Antonia, Kollár Attila, Felber Dietrich Denise, Kronig M N, Britschgi Christian, Rordorf Tamara, Jörger Markus, Krasniqi Fatime, Metaxas Yannis, Colombo Ilaria, Ribi Karin, Rothermundt Christian
Geriatric evaluation methods in oncology and their use in clinical studies: A systematic literature review.
Stueger A, Jörger M, De Nys K. Geriatric evaluation methods in oncology and their use in clinical studies: A systematic literature review. J Geriatr Oncol 2023:101684.
09.12.2023Geriatric evaluation methods in oncology and their use in clinical studies: A systematic literature review.
09.12.2023J Geriatr Oncol 2023:101684
Stueger Amelie, Jörger Markus, De Nys Katelijne
Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021.
Passweg J, Baldomero H, Ansari M, Arber C, Chalandon Y, Daskalakis M, Diepold M, Diesch-Furlanetto T, Duchosal M, Gerull S, Güngör T, Heim D, Hitz F, Holbro A, Masouridi-Levrat S, Nair G, Novak U, Pabst T, Renner C, Stussi G, Schneidawind D, Schanz U, Wannesson L, Halter J, Swiss Blood Stem Cell Transplantation Group (SBST). Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021. Hematol Oncol 2023
06.12.2023Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021.
06.12.2023Hematol Oncol 2023
Passweg Jakob R, Baldomero Helen, Ansari Marc, Arber Caroline, Chalandon Yves, Daskalakis Michael, Diepold Miriam, Diesch-Furlanetto Tamara, Duchosal Michel A, Gerull Sabine, Güngör Tayfun, Heim Dominik, Hitz Felicitas, Holbro Andreas, Masouridi-Levrat Stavroula, Nair Gayathri, Novak Urban, Pabst Thomas, Renner Christoph, Stussi Georg, Schneidawind Dominik, Schanz Urs, Wannesson Luciano, Halter Jörg P, Swiss Blood Stem Cell Transplantation Group (SBST)
A replicating LCMV-based vaccine for the treatment of solid tumors.
Purde M, Cupovic J, Palmowski Y, Makky A, Schmidt S, Rochwarger A, Hartmann F, Stemeseder F, Lercher A, Abdou M, Bomze D, Besse L, Berner F, Tüting T, Hölzel M, Bergthaler A, Kochanek S, Ludewig B, Lauterbach H, Orlinger K, Bald T, Schietinger A, Schürch C, Ring S, Flatz L. A replicating LCMV-based vaccine for the treatment of solid tumors. Mol Ther 2023
05.12.2023A replicating LCMV-based vaccine for the treatment of solid tumors.
05.12.2023Mol Ther 2023
Purde Mette-Triin, Cupovic Jovana, Palmowski Yannick A, Makky Ahmad, Schmidt Sarah, Rochwarger Alexander, Hartmann Fabienne, Stemeseder Felix, Lercher Alexander, Abdou Marie-Therese, Bomze David, Besse Lenka, Berner Fiamma, Tüting Thomas, Hölzel Michael, Bergthaler Andreas, Kochanek Stefan, Ludewig Burkhard, Lauterbach Henning, Orlinger Klaus K, Bald Tobias, Schietinger Andrea, Schürch Christian M, Ring Sandra Stephanie, Flatz Lukas
Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.
Bauer T, Santoro A, Lin C, Garrido-Laguna I, Jörger M, Greil R, Spreafico A, Yau T, Goebeler M, Hütter-Krönke M, Perotti A, Juif P, Lu D, Barys L, Cremasco V, Pelletier M, Evans H, Fabre C, Doi T. Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors. J Immunother Cancer 2023; 11
29.11.2023Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.
29.11.2023J Immunother Cancer 2023; 11
Bauer Todd M, Santoro Armando, Lin Chia-Chi, Garrido-Laguna Ignacio, Jörger Markus, Greil Richard, Spreafico Anna, Yau Thomas, Goebeler Maria-Elisabeth, Hütter-Krönke Marie Luise, Perotti Antonella, Juif Pierre-Eric, Lu Darlene, Barys Louise, Cremasco Viviana, Pelletier Marc, Evans Helen, Fabre Claire, Doi Toshikiko
CMR reveals myocardial damage from cardiotoxic oncologic therapies in breast cancer patients.
Kersten J, Fink V, Kersten M, May L, Nunn S, Tadic M, Huober J, Bekes I, Radermacher M, Hombach V, Rottbauer W, Buckert D. CMR reveals myocardial damage from cardiotoxic oncologic therapies in breast cancer patients. Int J Cardiovasc Imaging 2023
25.11.2023CMR reveals myocardial damage from cardiotoxic oncologic therapies in breast cancer patients.
25.11.2023Int J Cardiovasc Imaging 2023
Kersten Johannes, Fink Visnja, Kersten Maria, May Lisa, Nunn Samuel, Tadic Marijana, Huober Jens, Bekes Inga, Radermacher Michael, Hombach Vinzenz, Rottbauer Wolfgang, Buckert Dominik
Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.
Schuler A, Huser J, Schmid S, Schär S, Scherz A, Gautschi O, Mauti L, von Briel T, Waibel C, Wannesson L, Pankovics J, Mark M, Rothschild S, Addeo A, Janthur W, Siano M, Boos L, Britschgi C, Früh M. Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study. Lung Cancer 2023; 187:107427.
22.11.2023Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.
22.11.2023Lung Cancer 2023; 187:107427
Schuler Alexandra, Huser J, Schmid Sebastian M, Schär Sämi, Scherz Amina, Gautschi Oliver Pascal, Mauti Laetitia A, von Briel Thomas, Waibel Christine, Wannesson Luciano, Pankovics J, Mark Michael Thomas, Rothschild Sacha I, Addeo Alfredo, Janthur W, Siano Marco, Boos L, Britschgi Christian, Früh Martin